Three-in-one agonists for PPAR-a, PPAR-γ, and PPAR-d from traditional Chinese medicine

Journal of Biomolecular Structure and Dynamics

Volumn 30, Issue 6, 2012, Pages 662-683

  Chen, Kuan Chung ^a,b   Chang, Su Sen ^b   Huang, Hung Jin ^a,b   Lin, Tu Liang ^c   Wu, Yong Jiang ^d   Chen, Calvin Yu Chian ^a,b,e,f  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^d ZHEJIANG UNIVERSITY   (China)

^e ASIA UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

Author keywords

Docking; Molecular dynamics (MD); PPAR ; PPAR ; PPAR ; Traditional Chinese medicine (TCM)

Indexed keywords

3 [5 METHOXY 1 [(4 METHOXYPHENYL)SULFONYL] 1H INDOL 3 YL]PROPANOIC ACID; 3 O FERULOYLQUINIC ACID; 5 FERULOYLQUINIC ACID; ALANINE; ARGININE; BEROLINE; GLUTAMIC ACID; LYSINE; N [3 [[2 (4 CHLOROPHENYL) 5 METHYL 1,3 OXAZOL 4 YL]METHOXY]BENZYL] N (METHOXYCARBONYL)GLYCINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSMARINIC ACID; T 2384; THREONINE; TRYPTOPHAN BETAXANTHIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

AMINO ACID SEQUENCE; ARTICLE; CHINESE MEDICINE; CONTROLLED STUDY; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN INTERACTION; SCORING SYSTEM; CHEMICAL PHENOMENA; CHEMISTRY; DRUG POTENTIATION; HUMAN; HYDROGEN BOND; METHODOLOGY; MOLECULAR GENETICS; MOLECULAR LIBRARY; NUCLEOTIDE SEQUENCE; STRUCTURAL HOMOLOGY;

RUMEX;

AMINO ACID SEQUENCE; CONSERVED SEQUENCE; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYPOGLYCEMIC AGENTS; MEDICINE, CHINESE TRADITIONAL; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; PPAR ALPHA; PPAR DELTA; PPAR GAMMA; SMALL MOLECULE LIBRARIES; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 84871181814     PISSN: 07391102     EISSN: 15380254     Source Type: Journal    
DOI: 10.1080/07391102.2012.689699     Document Type: Article

References (75)

1. Artis, D.R., Lin, J.J., Zhang, C., Wang, W., Mehra, U., Perreault, M. Tobin, J.F. (2009). Scaffold-based discovery of indeglitazar, a PPAR pan-Active anti-diabetic agent. Proceedings of the National Academy of Sciences of the United States of America, 106, 262-267.
2. Billin, A.N. (2008). PPAR-beta/delta agonists for Type 2 diabetes and dyslipidemia: An adopted orphan still looking for a home. Expert Opinion on Investigational Drugs, 17, 1465-1471.
3. Brooks, B.R., Bruccoleri, R.E., Olafson, B.D., States, D.J., Swaminathan, S., & Karplus, M. (1983). CHARMM: A program for macromolecular energy minimization and dynamics calculations. Journal of Computational Chemistry, 4, 187-217.
4. Cambria, M.T., Di Marino, D., Falconi, M., Garavaglia, S., & Cambria, A. (2010). Docking simulation and competitive experiments validate the interaction between the 2,5-xylidine inhibitor and Rigidoporus lignosus laccase. Journal of Biomolecular Structure & Dynamics, 27, 501-510.
5. Chang, T.T., Chen, K.C., Chang, K.W., Chen, H.Y., Tsai, F.J., Sun, M.F., & Chen, C.Y.C. (2011). In silico pharmacology suggests ginger extracts may reduce stroke risks. Molecular Biosystems, 7, 2702-2710.
6. Chang, T.N., Huang, S.S., Chang, Y.S., Chang, C.I., Yang, H. L., Deng, J.S. Huang, G.J. (2011). Analgesic effects and mechanisms of anti-inflammation of taraxeren-3-one from Diospyros maritima in mice. Journal of Agricultural and Food Chemistry, 59, 9112-9119.
7. Chang, S.S., Huang, H.J., & Chen, C.Y.C. (2011a). High performance screening, structural and molecular dynamics analysis to identify H1 inhibitors from TCM Database@ Taiwan. Molecular Biosystems, 7, 3366-3374.
8. Chang, S.S., Huang, H.J., & Chen, C.Y.C. (2011b). Two birds with one stone? Possible dual-Targeting H1N1 inhibitors from traditional Chinese medicine PLoS Computational Biology, 7, e1002315.
9. Chang, T.T., Huang, H.J., Lee, K.J., Yu, H.W., Chen, H.Y., Tsai, F.J. Chen, C.Y.C. (2010). Key features for designing phosphodiesterase-5 inhibitors. Journal of Biomolecular Structure & Dynamics, 28, 309-321.
10. Chang, T.T., Sun, M.F., Chen, H.Y., Tsai, F.J., Fisher, M., Lin, J.G., & Chen, C.Y.C. (2011). Screening from the world's largest TCM database against H1N1 virus. Journal of Biomolecular Structure & Dynamics, 28, 773-786.
11. Chang, P.C., Wang, J.D., Lee, M.M., Chang, S.S., Tsai, T.Y., Chang, K.W. Chen, C.Y.C. (2011). Lose weight with traditional chinese medicine? Potential suppression of fat mass and obesity-Associated protein Journal of Biomolecular Structure & Dynamics, 29, 471-483.
12. Cheatham, W.W. (2010). Peroxisome proliferator-Activated receptor translational research and clinical experience. The American Journal of Clinical Nutrition, 91, 262S-266S.
13. Chen, C.Y.C. (2007). The molecular dynamic simulation of zolpidem interaction with gamma aminobutyric acid type A receptor. Journal of the Chinese Chemical Society, 54, 653-658.
14. Chen, C.Y.C. (2008a). Insights into the suanzaoren mechanism-From constructing the 3D structure of GABA-A receptor to its binding interaction analysis. Journal of the Chinese Institute of Chemical Engineers, 39, 663-671.
15. Chen, C.Y.C. (2008b). A novel perspective on designing the inhibitor of HER2 receptor. Journal of the Chinese Institute of Chemical Engineers, 39, 291-299.
16. Chen, C.Y.C. (2009a). Pharmacoinformatics approach for mPGES-1 in anti-inflammation by 3D-QSAR pharmacophore mapping. Journal of the Taiwan Institute of Chemical Engineers, 40, 155-161.
17. Chen, C.Y.C. (2009b). Computational screening and design of traditional Chinese medicine (TCM) to block phosphodiesterase-5. Journal of Molecular Graphics & Modelling, 28, 261-269.
18. Chen, C.Y.C. (2009c). Chemoinformatics and pharmacoinformatics approach for exploring the GABA-A agonist from Chinese herb suanzaoren. Journal of the Taiwan Institute of Chemical Engineers, 40, 36-47.
19. Chen, C.Y.C. (2009d). De novo design of novel selective COX-2 inhibitors: From virtual screening to pharmacophore analysis. Journal of the Taiwan Institute of Chemical Engineers, 40, 55-69.
20. Chen, C.Y.C. (2010a). Virtual screening and drug design for PDE-5 receptor from traditional Chinese medicine database. Journal of Biomolecular Structure & Dynamics, 27, 627-640.
21. Chen, C.Y.C. (2010b). Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/HSP90 dual-Targeted inhibitors. Journal of the Taiwan Institute of Chemical Engineers, 41, 143-149.
22. Chen, C.Y.C. (2011). TCM database@Taiwan: The world's largest traditional Chinese medicine database for drug screening in silico. PLoS ONE, 6, e15939.
23. Chen, C.Y., Chang, Y.H., Bau, D.T., Huang, H.J., Tsai, F.J., Tsai, C.H., & Chen, C.Y.C. (2009). Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis. Acta Pharmacologica Sinica, 30, 1186-1194.
24. Chen, K.C., Chang, K.W., Chen, H.Y., & Chen, C.Y.C. (2011). Traditional Chinese medicine, a solution for reducing dual stroke risk factors at once? Molecular Biosystems, 7, 2711-2719.
25. Chen, C.Y., & Chen, C.Y.C. (2010). Insights into designing the dual-Targeted HER2/HSP90 inhibitors. Journal of Molecular Graphics & Modelling, 29, 21-31.
26. Chen, K.-C., & Chen, C.Y.C. (2011). Stroke prevention by traditional Chinese medicine? A genetic algorithm, support vector machine and molecular dynamics approach Soft Matter, 7, 4001-4008.
27. Chen, C.Y.C., Chen, G.W., & Chen, W.Y.C. (2008). Molecular simulation of HER2/neu degradation by inhibiting HSP90. Journal of the Chinese Chemical Society, 55, 297-302.
28. Chen, C.Y., Huang, H.J., Tsai, F.J., & Chen, C.Y.C. (2010). Drug design for Influenza A virus subtype H1N1. Journal of the Taiwan Institute of Chemical Engineers, 41, 8-15.
29. Chen, K.C., Sun, M.F., Yang, S.C., Chang, S.S., Chen, H.Y., Tsai, F.J., & Chen, C.Y.C. (2011). Investigation into potent inflammation inhibitors from traditional Chinese medicine. Chemical Biology & Drug Design, 78, 679-688.
30. Cortopassi, W.A., Oliveira, A.A., Guimaraes, A.P., Renno, M. N., Krettli, A.U., & Franca, T.C. (2011). Docking studies on the binding of quinoline derivatives and hematin to Plasmodium falciparum lactate dehydrogenase. Journal of Biomolecular Structure & Dynamics, 29, 207-218.
31. Duval, C., Muller, M., & Kersten, S. (2007). PPARalpha and dyslipidemia. Biochimica et Biophysica Acta, 1771, 961-971.
32. Fajas, L., Debril, M.B., & Auwerx, J. (2001). Peroxisome proliferator-Activated receptor-gamma: From adipogenesis to carcinogenesis. Journal of Molecular Endocrinology, 27, 1-9.
33. Fletcher, R. (1969). Optimization. New York, NY: Academic Press.
34. Fletcher, R., & Reeves, C.M. (1964). Function minimization by conjugate gradients. Computer Journal, 7, 149-154.
35. Furukawa, A., Arita, T., Satoh, S., Wakabayashi, K., Hayashi, S., Matsui, Y. Ohsumi, J. (2010). Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives. Bioorganic & Medicinal Chemistry Letters, 20, 2095-2098.
36. Ghosh, M., Ai, Y., Narko, K., Wang, Z., Peters, J.M., & Hla, T. (2009). PPARdelta is pro-Tumorigenic in a mouse model of COX-2-induced mammary cancer. Prostaglandins & Other Lipid Mediators, 88, 97-100.
37. Guan, Y. (2004). Peroxisome proliferator-Activated receptor family and its relationship to renal complications of the metabolic syndrome. Journal of the American Society of Nephrology: JASN, 15, 2801-2815.
38. Guan, Y., Zhang, Y., Davis, L., & Breyer, M.D. (1997). Expression of peroxisome proliferator-Activated receptors in urinary tract of rabbits and humans. The American Journal of Physiology, 273, F1013-1022.
39. Guimaraes, A.P., Oliveira, A.A., da Cunha, E.F., Ramalho, T. C., & Franca, T.C. (2011). Design of new chemotherapeutics against the deadly anthrax disease. Docking and molecular dynamics studies of inhibitors containing pyrrolidine and riboamidrazone rings on nucleoside hydrolase from Bacillus anthracis. Journal of Biomolecular Structure & Dynamics, 28, 455-469.
40. Guri, A.J., Hontecillas, R., & Bassaganya-Riera, J. (2006). Peroxisome proliferator-Activated receptors: Bridging metabolic syndrome with molecular nutrition. Clinical Nutrition, 25, 871-885.
41. Holness, M.J., Smith, N.D., Greenwood, G.K., & Sugden, M. C. (2007). PPARalpha activation reverses adverse effects induced by high-saturated-fat feeding on pancreatic betacell function in late pregnancy. American Journal of Physiology Endocrinology and Metabolism, 292, E1087-1094.
42. Huang, G.J., Deng, J.S., Huang, S.S., Shao, Y.Y., Chen, C.C., & Kuo, Y.H. (2012a). Protective effect of antrosterol from Antrodia camphorata submerged whole broth against carbon tetrachloride-induced acute liver injury in mice. Food Chemistry, 132, 709-716.
43. Huang, G.J., Deng, J.S., Liao, J.C., Hou, W.C., Wang, S.Y., Sung, P.J., & Kuo, Y.H. (2012b). Inducible nitric oxide synthase and cyclooxygenase-2 participate in anti-inflammatory activity of imperatorin from Glehnia littoralis. Journal of Agricultural and Food Chemistry, 60, 1673-1681.
44. Huang, H.J., Lee, K.J., Yu, H.W., Chen, H.Y., Tsai, F.J., & Chen, C.Y.C. (2010). A novel strategy for designing the selective PPAR agonist by the 'sum of activity' model. Journal of Biomolecular Structure & Dynamics, 28, 187-200.
45. Kahlon, A.K., Roy, S., & Sharma, A. (2010). Molecular docking studies to map the binding site of squalene synthase inhibitors on dehydrosqualene synthase of Staphylococcus aureus. Journal of Biomolecular Structure & Dynamics, 28, 201-210.
46. Kersten, S., Mandard, S., Escher, P., Gonzalez, F.J., Tafuri, S., Desvergne, B., & Wahli, W. (2001). The peroxisome proliferator-Activated receptor alpha regulates amino acid metabolism. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 15, 1971-1978.
47. Kramer, D.K., Al-Khalili, L., Guigas, B., Leng, Y., Garcia-Roves, P.M., & Krook, A. (2007). Role of AMP kinase and PPAR delta in the regulation of lipid and glucose metabolism in human skeletal muscle. The Journal of Biological Chemistry, 282, 19313-19320.
48. Li, J., Kennedy, L.J., Shi, Y., Tao, S., Ye, X.Y., Chen, S.Y., Tino, J.A. (2010). Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5- methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)am ino)acetic acid (BMS-687453). Journal of Medicinal Chemistry, 53, 2854-2864.
49. Li, Y.T., Li, L., Chen, J., Hu, T.C., Huang, J., Guo, Y.W., Shen, X. (2009). 7-Chloroarctinone-b as a new selective PPARgamma antagonist potently blocks adipocyte differentiation. Acta Pharmacologica Sinica, 30, 1351-1358.
50. Li, Y., Wang, Z., Furukawa, N., Est, P., Weiszmann, J., Lee, G., Chen, J.L. (2008). T2384, a novel antidiabetic agent with unique peroxisome proliferator-Activated receptor gamma binding properties. The Journal of Biological Chemistry, 283, 9168-9176.
51. Lin, C.H., Chang, T.T., Sun, M.F., Chen, H.Y., Tsai, F.J., Chang, K.L., Chen, C.Y.C. (2011). Potent inhibitor design against H1N1 swine influenza: Structure-based and molecular dynamics analysis for M2 inhibitors from traditional Chinese medicine database. Journal of Biomolecular Structure & Dynamics, 28, 471-482.
52. Lin, T.L., & Song, G. (2011). Efficient mapping of ligand migration channel networks in dynamic proteins. Proteins-Structure Function and Genetics, 79, 2475-2490.
53. Mansouri-Torshizi, H., Saeidifar, M., Divsalar, A., & Saboury, A.A. (2011). Study on interaction of DNA from calf thymus with 1,10- phenanthrolinehexyldithiocarbamatopalladium (II) nitrate as potential antitumor agent. Journal of Biomolecular Structure & Dynamics, 28, 805-814.
54. Mehrnejad, F., & Zarei, M. (2010). Molecular dynamics simulation study of the interaction of Piscidin 1 with DPPC bilayers: Structure-Activity relationship. Journal of Biomolecular Structure & Dynamics, 27, 551-560.
55. Michalik, L., Auwerx, J., Berger, J.P., Chatterjee, V.K., Glass, C.K., Gonzalez, F.J., Wahli, W. (2006). International union of pharmacology. LXI. Peroxisome proliferatoractivated receptors. Pharmacological Reviews, 58, 726-741.
56. Mukherjee, R., Jow, L., Noonan, D., & McDonnell, D.P. (1994). Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. The Journal of Steroid Biochemistry and Molecular Biology, 51, 157-166.
57. Pankratov, A.N., Tsivileva, O.M., Drevko, B.I., & Nikitina, V. E. (2011). Compounds of the 1,5-di(4-R-phenyl)-3-selenopentanediones-1,5 series interaction with the basidiomycete Lentinula edodes lectins: Computations and experiment. Journal of Biomolecular Structure & Dynamics, 28, 969-974.
58. Peters, J.M., Lee, S.S., Li, W., Ward, J.M., Gavrilova, O., Everett, C., Gonzalez, F.J. (2000). Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-Activated receptor beta (delta). Molecular and Cellular Biology, 20, 5119-5128.
59. Richardson, D.C., Lovell, S.C., Davis, I.W., Adrendall, W.B., de Bakker, P.I.W., Word, J.M., Richardson, J.S. (2003). Structure validation by C alpha geometry: Phi, psi and C beta deviation. Proteins-Structure Function and Genetics, 50, 437-450.
60. Rotman, N., & Wahli, W. (2009). Fatty acid synthesis and PPARalpha hand in hand. Chemistry & Biology, 16, 801-802.
61. Semighini, E.P., Resende, J.A., de Andrade, P., Morais, P.A., Carvalho, I., Taft, C.A., & Silva, C.H. (2011). Using computer-Aided drug design and medicinal chemistry strategies in the fight against diabetes. Journal of Biomolecular Structure & Dynamics, 28, 787-796.
62. Sharma, A.M., & Staels, B. (2007). Review: Peroxisome proliferator-Activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. The Journal of Clinical Endocrinology and Metabolism, 92, 386-395.
63. Sotiropoulos, K.B., Clermont, A., Yasuda, Y., Rask-Madsen, C., Mastumoto, M., Takahashi, J., King, G.L. (2006). Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: Novel mechanism for PPARgamma agonist's effects on edema and weight gain. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology, 20, 1203-1205.
64. Staels, B. (2005). Fluid retention mediated by renal PPARgamma. Cell Metabolism, 2, 77-78.
65. Sun, M.F., Chen, H.Y., Tsai, F.J., Lui, S.H., & Chen, C.Y.C. (2011). Search for novel remedies to augment radiation resistance of inhabitants of Fukushima and Chernobyl disasters: Identifying DNA repair protein XRCC4 inhibitors. Journal of Biomolecular Structure & Dynamics, 29, 325-337.
66. Venkatachalam, C.M., Jiang, X., Oldfield, T., & Waldman, M. (2003). LigandFit: A novel method for the shape-directed rapid docking of ligands to protein active sites. Journal of Molecular Graphics & Modelling, 21, 289-307.
67. Viana Abranches, M., Esteves de Oliveira, F.C., & Bressan, J. (2011). Peroxisome proliferator-Activated receptor: Effects on nutritional homeostasis, obesity and diabetes mellitus. Nutricion Hospitalaria: Organo oficial de la Sociedad Espanola de Nutricion Parenteral y Enteral, 26, 271-279.
68. Wang, Y.X., Lee, C.H., Tiep, S., Yu, R.T., Ham, J., Kang, H., & Evans, R.M. (2003). Peroxisome-proliferator-Activated receptor delta activates fat metabolism to prevent obesity. Cell, 113, 159-170.
69. Wu, J.S., Cheung, W.M., Tsai, Y.S., Chen, Y.T., Fong, W.H., Tsai, H.D., Lin, T.N. (2009). Ligand-Activated peroxisome proliferator-Activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation, 119, 1124-1134.
70. Wu, K.K., & Liou, J.Y. (2009). Cyclooxygenase inhibitors induce colon cancer cell apoptosis via PPARdelta -> 14-3-3epsilon pathway. Methods in Molecular Biology, 512, 295-307.
71. Xie, H.Z., Liu, L.Y., Ren, J.X., Zhou, J.P., Zheng, R.L., Li, L. L., & Yang, S.Y. (2011). Pharmacophore modeling and hybrid virtual screening for the discovery of novel IkappaB kinase 2 (IKK2) inhibitors. Journal of Biomolecular Structure & Dynamics, 29, 165-179.
72. Xu, H.E., Lambert, M.H., Montana, V.G., Parks, D.J., Blanchard, S.G., Brown, P.J., Milburn, M.V. (1999). Molecular recognition of fatty acids by peroxisome proliferatoractivated receptors. Molecular Cell, 3, 397-403.
73. Xu, H.E., Lambert, M.H., Montana, V.G., Plunket, K.D., Moore, L.B., Collins, J.L., Willson, T.M. (2001). Structural determinants of ligand binding selectivity between the peroxisome proliferator-Activated receptors. Proceedings of the National Academy of Sciences of the United States of America, 98, 13919-13924.
74. Yang, S.C., Chang, S.S., Chen, H.Y., & Chen, C.Y.C. (2011). Identification of potent EGFR inhibitors from TCM Database@ Taiwan. PLoS Computational Biology, 7, e1002189.
75. Zoete, V., Grosdidier, A., & Michielin, O. (2007). Peroxisome proliferator-Activated receptor structures: Ligand specificity, molecular switch and interactions with regulators. Biochimica et Biophysica Acta, 1771, 915-925.